Table 1.
Patient characteristics
| QRS <150 ms (n=139) |
QRS ⩾150 ms (n=26) | All patients (n=165) |
|
| Male/female (%) | 80.6/19.4 | 76.9/23.1 | 80.0/20.0 |
| Age (years) (mean (SD)) | 61.8 (9.7) | 61.7 (9.9) | 61.8 (9.7) |
| Age range (years) | 14–82 | 31–79 | 14– 82 |
| EF (%) (mean (SD)) | 32.9 (13.3) | 30.6 (15.0) | 32.5 (13.6) |
| EF range (%) | 7 to 83 | 10 to 61 | 7 to 83 |
| Underlying disease (n) | |||
| CAD | 104 (74.8%) | 16 (61.5%) | 120 (72.7%) |
| DCM | 24 (17.3%) | 5 (19.2%) | 29 (17.6%) |
| ARVCM | 3 (2.2%) | 1 (3.8%) | 4 (2.4%) |
| Valvar | 5 (3.6%) | 4 (15.4%) | 9 (5.5%) |
| Other | 3 (2.2%) | – | 3 (1.8%) |
| Presenting arrhythmia (n) | |||
| CA | 86 (61.7%) | 18 (69.1%) | 104 (63.0%) |
| Only VT | 51 (36.7%) | 9 (34.6%) | 60 (36.4%) |
| Only VF | 50 (36.0%) | 8 (30.8%) | 58 (35.2%) |
| VT+VF | 29 (20.9%) | 8 (30.8%) | 37 (22.4%) |
| Others | 9 (6.5%) | 1 (3.8%) | 10 (6.1) |
| Drug treatment (n) | |||
| Class I AA drugs | 2 (1,5%) | – | 2 (1.3%) |
| Class III AA drugs | 30 (22.6%) | 8 (33.3%) | 38 (24.2%) |
| β Blocker | 38 (28.4%) | 3 (12.5%) | 41 (25.9%) |
| ACE inhibitor | 94 (70.1%) | 21 (87.5%) | 115 (72.8%) |
| Diuretic | 89 (66.4%) | 19 (79.2%) | 108 (68.4%) |
| Digitalis | 102 (76.1%) | 20 (83.3%) | 122 (77.2%) |
| Lead system (n) | |||
| Transvenous | 84 (60.4%) | 18 (69.2%) | 102 (61.8%) |
| Transvenous-subcutaneous | 53 (38.1%) | 8 (30.8%) | 61 (37.0%) |
| Epicardial | 2 (1.4%) | – | 2 (1.2%) |
AA, antiarrhythmic; ACE, angiotensin converting enzyme; ARVCM, arrhythmogenic right ventricular cardiomyopathy; CA, cardiac arrest; CAD, coronary artery disease; DCM, dilated cardiomyopathy;
EF, ejection fraction; VF, ventricular fibrillation; VT, ventricular tachycardia.